China Sky One Medical Receives Medical Industry Awards

HARBIN, China, Jan. 27, 2011 /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), the Company's wholly owned operating subsidiary, was named a "Top Ten Branded Company Trusted by Consumers" according to research and rankings conducted jointly by influential and authoritative institutions including, China Medical Association, China Pharmaceutical Association, China Medical Brand Research Association, and the Brand Research Center of Business Times Newspaper. The designation is based on product quality and brand recognition among domestic Chinese pharmaceutical companies. Additionally, China Sky One's "Yu Fu" branded Compound Camphor Cream was named a "Top Ten Brand for Skin Treatment Medicine" and Mr. Yan-qing Liu, the Company's Chairman and CEO, was elected as a "Top Ten Trusted Entrepreneur in China's Medical Industry." Please click here to view certificates of these awards.

China Sky One Medical Receives Medical Industry Awards

"We are honored to receive these awards and appreciate the ongoing support of our loyal customers. Entering 2011, we will strive to maintain the highest product quality standards and introduce more innovative new products to address the needs of China's large and growing health care market," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company, the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn.

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the Company's brand recognition and product quality. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.